Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- ANNALS OF HEMATOLOGY105(7) · #315 · 2026
- 피인용
- Web of Science 1Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 2.4
- ISSN
- 0939-5555
저자
- Lee, Seok제1저자Ewha Womans Univ, Mokdong Hosp, Dept Hematol, Seoul, South Korea
- Kim, Hyeoung-JoonChonnam Natl Univ, Hematol Oncol, Hwasun Hosp, Hwasun, Jeonranam Do, South Korea
- Cheong, June-WonYonsei Univ, Gangnam Severance Hosp, Div Hematol, Coll Med, Seoul, South Korea
- 신호진Pusan Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol, Pusan, South Korea
- Kong, Jee HyunWonju Severance Christian Hosp, Dept Internal Med, Div Oncol & Hematol, Wonju, South Korea
- Sohn, Sang KyunKyungpook Natl Univ Hosp, Dept Hematol Oncol, Daegu, South Korea
- Yoon, Sung-SooSeoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
- Zang, Dae YoungHallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Hematol Oncol, Anyang Si, South Korea
- Jung, Chul WonSungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea
- Kim, Jeong-ACatholic Univ Korea, St Vincents Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
- Lee, Sung-EunCatholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hematol, Seoul, South Korea
- Lee, Won SikInje Univ, Dept Hematol & Oncol, Internal Med, Busan Paik Hosp,Coll Med, Busan, South Korea
- Choi, YunsukUniv Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea
- Kim, InhoSeoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
- Han, Jae JoonKyung Hee Univ, Coll Med, Dept Hematol & Med Oncol, Seoul, South Korea
- Kim, Min KyoungYeungnam Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Daegu, South Korea
- Chong, So YoungCHA Univ, Sch Med, Dept Internal Med, CHA Bundang Med Ctr, Seongnam, South Korea
- Kim, Da JungKosin Univ, Gospel Hosp, Dept Internal Med, Div Hematol Oncol,Coll Med, Busan, South Korea
- Jo, Deog-YeonChungnam Natl Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Daejeon, South Korea
- Kim, HawkGachon Univ, Gil Med Ctr, Coll Med, Div Hematol, Incheon, South Korea
- Kwak, Jae-YongJeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, South Korea
- Lee, Je-HwanUniv Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea
- Uhm, JieunHanyang Univ, Seoul Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Seoul, South Korea
- Lee, SewonEwha Womans Univ, Mokdong Hosp, Dept Hematol, Seoul, South Korea
- Lee, Min-YiKorea Otsuka Pharmaceut Co Ltd, Seoul, South Korea
- Kim, Dong-Wook교신저자Uijeongbu Eulji Med Ctr, Dept Hematol, Uijongbu, South Korea
초록
To evaluate the real-world efficacy and safety of ponatinib, we conducted a multicenter, prospective post-marketing surveillance study in patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), who were resistant or intolerant to prior tyrosine kinase inhibitors (TKIs) or harbored the T315I mutation. A total of 148 patients were enrolled across 24 sites: 115 with CML (92 CP-CML, 12 AP-CML, 11 BP-CML) and 33 with Ph + ALL. Ponatinib was administered as third-line therapy in 70 patients (47.3%), and 127 (85.8%) initiated treatment at 45 mg once daily. Sixty-three patients (42.6%) began ponatinib due to resistance or intolerance to prior TKIs. In CP-CML, the overall major molecular response (MMR) rate was 43.2% (35/81), with a cumulative MMR incidence of 23.9% at week 24 among patients without prior MMR. In Ph + ALL, the overall MMR and complete cytogenetic response (CCyR) rates were 82.4% (14/17) and 75.0% (3/4), respectively. CP-CML patients receiving ponatinib as earlier-line therapy achieved higher MR4.5 rates than those treated later (47.4% vs. 16.1%, p = 0.011). The most common adverse drug reactions were rash (21.6%, 32/148), hypertension (12.2%, 18/148), and pyrexia (10.1%, 15/148); two vascular occlusive events occurred. Ponatinib showed favorable real-world efficacy and manageable safety in Korean patients. Early, high-dose therapy suggests a trend toward deep molecular responses, supporting its clinical benefit in real-world practice. (ClinicalTrials.gov Identifier: NCT03709017; registered October 15, 2018)
키워드
PonatinibPost-marketing surveillanceChronic myeloid leukemiaAcute lymphoblastic leukemiaASIAN PATIENTS
식별자
- Scopus EID
- 2-s2.0-105043758430
- WoS UID
- 001810672700001



로그인
연구물 목록으로